Welcome to our dedicated page for LEMAITRE VASCULAR SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LEMAITRE VASCULAR's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LEMAITRE VASCULAR's regulatory disclosures and financial reporting.
LeMaitre Vascular’s President and Director David B. Roberts reported an open-market sale of 3,311.68 shares of common stock on March 11, 2026 at a weighted average price of $107.6752 per share. After this transaction, he directly holds 14,667.32 shares of the company’s common stock.
The sale was executed in multiple trades at prices ranging from $106.52 to $108.65, with the weighted average reported. Roberts has undertaken to provide detailed trade and pricing information to the company, its shareholders, or the SEC staff upon request.
LeMaitre Vascular’s Chief Financial Officer Dorian Paul LeBlanc reported routine equity compensation activity. On March 10, 2026, he exercised dividend equivalent rights into 2 shares of common stock at $0.00 per share and now holds 9.3269 dividend equivalent rights. He also holds 2,302 shares of common stock directly after these transactions.
The filing shows 96 shares of common stock were withheld at $109.20 per share to satisfy tax obligations on restricted stock units that vested from an award granted on March 10, 2025. The tax withholding is characterized as an exempt sale under Rule 16b-3(e) and does not reflect an open-market trade.
LMAT files a Form 144 to offer 2,625 shares of Common Stock for sale. The notice states the planned sale arises from a stock option exercise and is dated 03/11/2026.
The filing also records a prior sale of 1,044 shares on 02/27/2026 by Trent G. Kamke for $115,142.76.
LMAT insider sale disclosure: A Form 144 lists a reported sale of 8,464 shares of Common Stock by David B. Roberts on 02/27/2026 for $903,957.00. The filing also lists 3,312 Common shares tied to equity compensation (stock option exercises and RSUs) dated 12/02/2024.
LeMaitre Vascular director Martha Shadan reported equity-based compensation on common stock. On February 26, 2026, she acquired 476 shares of common stock at a price of $0.0000 per share as a grant or award. She also acquired 1 additional common share through the exercise of a dividend equivalent right linked one-for-one to common stock. These transactions stem from a Performance Share Unit award originally granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remaining portions scheduled to vest in equal annual installments on the grant date anniversaries over the next two years.
LeMaitre Vascular director John A. Roush reported equity awards and vesting activity, not open‑market trades. On February 26, 2026, he received a grant of 476 shares of common stock and 1 share from the exercise of dividend equivalent rights, bringing his directly held common stock to 3,942 shares. Related derivative dividend equivalent rights totaled 2.8963 following settlement linked to a Performance Share Unit (PSU) award granted on December 6, 2024, which vested one‑third when the performance condition was met, with the remainder vesting in equal annual installments over the next two years. An additional 181 shares are held indirectly by his spouse.
LeMaitre Vascular director Bridget A. Ross reported acquiring company stock through equity awards. On February 26, 2026 she received 476 shares of common stock upon partial vesting of a performance share unit award, plus 1 share released from dividend equivalent rights, bringing her direct holdings to 3,942 shares.
LeMaitre Vascular director John James O'Connor reported equity awards and related conversions, not open-market trading. On February 26, 2026 he acquired 476 shares of common stock at $0.0000 per share as a grant or award, bringing his direct common stock holdings to 62,826 shares, then to 62,827 shares after a related derivative conversion.
He also exercised 1 dividend equivalent right and converted it into 1 share of common stock, and now holds 2.8963 dividend equivalent rights. Footnotes explain these transactions relate to a Performance Share Unit award granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remainder vesting in equal annual installments over the next two years.
LeMaitre Vascular director Lawrence J. Jasinski reported equity awards tied to performance share units. On February 26, 2026, he acquired 476 shares of common stock at no cost upon settlement of a PSU award granted on December 6, 2024, plus 1 additional common share from a derivative exercise.
The PSU award vested one‑third when the performance condition was determined satisfied on February 26, 2026, with the remaining two‑thirds vesting in equal annual installments over the next two years. Related dividend equivalent rights, economically equal to common stock, now total 2.8963 rights.
LEMAITRE VASCULAR director Joseph P. Pellegrino Jr. reported share acquisitions tied to equity compensation, not open-market buying or selling. On February 26, 2026, he received 1,893 shares of common stock as part of a performance share unit (PSU) award granted on December 6, 2024, after 25% of the award vested upon satisfaction of a performance condition.
He also acquired 4 dividend equivalent rights, which were exercised into 4 shares of common stock at a price of $0.00 per share. Each dividend equivalent right is the economic equivalent of one share of common stock and was released in connection with the PSU vesting. Following these transactions, he directly owned 12,080 shares of common stock and 11.4826 dividend equivalent rights, reflecting routine equity-based compensation rather than discretionary trading.